DE60238945D1 - Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist - Google Patents

Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist

Info

Publication number
DE60238945D1
DE60238945D1 DE60238945T DE60238945T DE60238945D1 DE 60238945 D1 DE60238945 D1 DE 60238945D1 DE 60238945 T DE60238945 T DE 60238945T DE 60238945 T DE60238945 T DE 60238945T DE 60238945 D1 DE60238945 D1 DE 60238945D1
Authority
DE
Germany
Prior art keywords
research
diseases
zelltod
diagnosis
involved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238945T
Other languages
English (en)
Inventor
Arturo Leone
Maria Caterina Turco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biouniversa SRL
Original Assignee
Biouniversa SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa SRL filed Critical Biouniversa SRL
Application granted granted Critical
Publication of DE60238945D1 publication Critical patent/DE60238945D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE60238945T 2001-12-28 2002-12-30 Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist Expired - Lifetime DE60238945D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01830834A EP1323733A1 (de) 2001-12-28 2001-12-28 BAG3-Nukleotid- und Proteinsequenzen zur Nutzung in Forschung, Diagnose und der Behandlung von Krankheiten, an denen Zelltod beteiligt ist
PCT/EP2002/014802 WO2003055908A2 (en) 2001-12-28 2002-12-30 Bag3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases

Publications (1)

Publication Number Publication Date
DE60238945D1 true DE60238945D1 (de) 2011-02-24

Family

ID=8184857

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238945T Expired - Lifetime DE60238945D1 (de) 2001-12-28 2002-12-30 Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist

Country Status (11)

Country Link
US (2) US7537760B2 (de)
EP (2) EP1323733A1 (de)
AT (1) ATE495193T1 (de)
AU (1) AU2002364302A1 (de)
CA (1) CA2471924C (de)
CY (1) CY1111371T1 (de)
DE (1) DE60238945D1 (de)
DK (1) DK1465927T3 (de)
ES (1) ES2359396T3 (de)
SI (1) SI1465927T1 (de)
WO (1) WO2003055908A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1397083B1 (it) * 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
KR101436684B1 (ko) 2012-03-09 2014-09-01 가톨릭대학교 산학협력단 저산소성 허혈 예방 또는 치료용 조성물
ITMI20130403A1 (it) * 2013-03-18 2014-09-19 Biouniversa Srl Anticorpi anti-bag3 per uso terapeutico
EP2676966A1 (de) 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 als biochemisches Serum und Gewebemarker
ITMI20131351A1 (it) 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
CA3228845A1 (en) 2014-01-31 2015-08-06 Temple University Of The Commonwealth System Of Higher Education Bag3 and uses thereof in the treatment of heart failure with reduced ejection fraction
ITUB20155097A1 (it) * 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
IT201600069391A1 (it) * 2016-07-04 2016-10-04 Univ Degli Studi Di Salerno Uso della proteina bag3 e suoi frammenti peptidici per il controllo dell’omeostasi vascolare
IT201600111877A1 (it) 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
EP3658582A1 (de) * 2017-07-28 2020-06-03 Intrepida Bio, Inc. Anti-bag3-antikörper als therapeutisches reagenz bei kardiovaskulären erkrankungen
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
CA3235431A1 (en) * 2021-10-22 2023-04-27 Arthur M. Feldman Bag3 methods and uses for treatment of inflammation
WO2023215266A1 (en) * 2022-05-03 2023-11-09 Temple University Of The Commonwealth System Of Higher Education Bag3 and protein quality control in the brain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652223A (en) * 1994-03-14 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA encoding CAI resistance proteins and uses thereof
JPH10327872A (ja) * 1997-05-30 1998-12-15 Otsuka Pharmaceut Co Ltd Ｂｃｌ−２相互作用蛋白遺伝子ｂｉｓ
WO2000014106A1 (en) * 1998-09-09 2000-03-16 The Burnham Institute Novel bag proteins and nucleic acid molecules encoding them
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them

Also Published As

Publication number Publication date
AU2002364302A8 (en) 2003-07-15
US20050176660A1 (en) 2005-08-11
AU2002364302A1 (en) 2003-07-15
DK1465927T3 (da) 2011-04-18
EP1465927A2 (de) 2004-10-13
US20090306192A1 (en) 2009-12-10
EP1465927B1 (de) 2011-01-12
ATE495193T1 (de) 2011-01-15
SI1465927T1 (sl) 2011-05-31
US7537760B2 (en) 2009-05-26
WO2003055908A3 (en) 2004-03-11
CA2471924C (en) 2013-11-12
ES2359396T3 (es) 2011-05-23
CY1111371T1 (el) 2015-08-05
CA2471924A1 (en) 2003-07-10
WO2003055908A2 (en) 2003-07-10
EP1323733A1 (de) 2003-07-02

Similar Documents

Publication Publication Date Title
CY1111371T1 (el) Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE516042T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
NO20080361L (no) Preparater og fremgangsmater for diagnostiseringer og behandlinger av tumor
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
ATE522623T1 (de) Zusammensetzungen und verfahren zur behandlung und diagnose von lungentumoren
DE60234793D1 (de) LIVP Stamm von Vaccinia-Virus zur Diagnose und Behandlung von Tumoren
ATE531729T1 (de) Kdr-peptide und diese enthaltende impfstoffe
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
ATE481978T1 (de) Zusammensetzungen und verfahren zur behandlung von herzkrankheiten
DK1450799T5 (da) Arulurinstofforbindelser sammen med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
ATE411805T1 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
DE69510810D1 (de) Lamanin-ketten: diagnostische und therapeutische verwendung
ATE350385T1 (de) Neue aryl fructose-1,6-bisphosphatase inhibitoren
DE60027415D1 (de) Zusammensetzung für die Verhinderung der Glattmuskelkrankheiten, die Ascorbat, Arginin und Magnesium enthält
BRPI0409359A (pt) análogos quiméricos de somatostatina-dopamina
ATE384437T1 (de) N-thio-nicotinamid derivate und verwandte verbindungen zur verwendung als schädlingsbekämpfungsmittel
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE306283T1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln
ATE414539T1 (de) Verfahren und materialien zur behandlung und diagnose von mit kallikrein-6 zusammenhängenden entzündlichen zuständen
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE602004024992D1 (de) Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten
ATE403716T1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
ATE364180T1 (de) Screeningverfahren mit bnpi und dnpi